Tempo Therapeutics Patent Portfolio Analysis

A single pulse, twelve years after founding

The round is $14.5M, announced on 16 September 2026. The named participants are the National Science Foundation, Johnson & Johnson Services, Inc., Gideon Strategic Partners, Mesa Verde Venture Partners and YK Bioventures. A grant agency and a corporate name sitting in the same line is worth noting on its own, because the two arrive for different reasons and rarely on the same schedule.

The company was founded in 2014. That is twelve years of work before this pulse, and the public record of it is thin by design: patents publish late, and the last one to surface did so in June 2024, twenty-seven months before this announcement. Anything filed since then is still invisible. What follows is everything the file actually shows, which is less than the company knows and more than it says.

Three ticks, and a seven year silence

Three families. One solid, two thin. The first filing is dated 22 December 2017, and it is the granted one, which makes it enforceable today rather than at some point after examination. The other two both entered in 2024, the most recent on 25 June. Between those bookends there is nothing published at all: a gap of more than six years with no new family surfacing.

The titles are plain. Methods and systems for treating a site of a medical implant. Hydrogel formulations and methods of use thereof. Annealed microgel particle systems and methods. Read as a set, the 2024 pair looks like an elaboration of the 2017 position rather than a turn toward something new. The company did not broaden its filing. It went back to the same ground and staked more of it.

Three families is not a portfolio strategy. It is a decision about where to be precise.

Materials first, medicine second, chemistry at the edge

A61L is the widest band by a long way. That is the materials and sterilisation side of the classification, not the drug side. A61K, medicinal preparations, and A61P sit behind it at equal weight. B01J appears on a single family and nothing more, a thin edge on the diagram rather than a direction.

The shape matters because it tells you what the claims are really about. A portfolio anchored in A61L is claiming the substance and its handling. The A61K and A61P overlap means those same filings also reach toward use, which is where value tends to concentrate, but the centre of gravity is the material itself. That is a materials position wearing a therapeutics label.

One inventor present on every single filing

Five inventors are named across the three families. Westbrook Weaver appears on all three. So does Stephanie Deshayes. Samuel Timko is on two. The remaining two names appear once each. There is no widening bench here and no sign of the pattern you see when a team scales: a founding pair on the early work, then new names taking over the later families.

Instead the 2024 filings carry the same signatures as the 2017 one. That is continuity, and it is the clearest thing in the file. The people who defined the original position are still the people writing the claims seven years later. It also means the technical knowledge is concentrated in very few heads, which is the ordinary condition of a company this size.

A small circle among very large ones

On the same scale, the other names filing in these CPC groups over the last five years are enormous. Oreal at 1,819 families. Unilever Global Ip at 418, Unilever Ip B V at 393, Conopco Dba Unilever at 388. Procter & Gamble at 341. Cosmax at 306. Tempo Therapeutics is the small circle, at three. Nothing about their businesses is on the record here. What is on the record is that they file where these claims sit.

In a space that busy, count is a poor measure of anything. Scope is the whole question. And the citations that have accumulated point somewhere unexpected: University of California six times, Cedars Sinai Medical Center three, Brown University three, University of Florida two, Ut Battelle two. Academic and clinical institutions, not the volume filers. The work is being read by researchers while sitting in a classification crowded with consumer chemistry.

Three families in a group with thousands means the claims either hold precisely or they hold nothing.

What the next publication will have to prove

The thread runs the whole way through. A 2017 filing that is now granted. A six year silence. Two more families in 2024 on the same ground, from the same hands. Claims centred on materials rather than medicine, in a classification where other assignees file by the hundred. And a $14.5M round arriving twenty-seven months after the last thing the public can read.

That is a narrow, deliberate position held by very few people for a long time, funded by a grant agency and a corporate name at the same moment. The record does not tell you whether the scope is wide enough to matter. It tells you exactly where to look when the next filings publish, and what the 2024 pair was already trying to secure.